OmniAb, Inc. - Common Stock (OABI)

OmniAb (NASDAQ:OABI) Chief Financial Officer Kurt Gustafson outlined the company’s antibody-discovery platform, partner pipeline and revenue model during a company presentation, emphasizing a strategy built around licensing technology to pharmaceutical and biotechnology companies rather than develop

OmniAb (NASDAQ:OABI) used its investor and analyst day to outline its strategy for expanding royalty-bearing partnerships, commercializing its xPloration screening platform and entering the peptide-discovery market through its newly introduced OmniTides platform. Management said the company has bui

Clinical programs advance as OmniAb raises full-year revenue guidance to $32M-$36M.

OmniAb (NASDAQ:OABI) reported higher second-quarter revenue and a narrower net loss as milestone payments from partner programs increased, while the company raised its full-year 2026 revenue and year-end cash outlook. Revenue for the second quarter totaled $13.4 million, compared with $3.9 million

OmniAb (OABI) Q1 2026 Earnings Transcript

OmniAb (NASDAQ:OABI) reported first-quarter 2026 results that management characterized as a “very strong start to the year,” driven primarily by clinical progress across its partner portfolio and associated milestone revenue. Partner program progress drives revenue outperformance President and CEO

OmniAb (OABI) Q4 2025 Earnings Call Transcript

Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based model.